Evidence map›Paper›PMID 38881978›Full record

ArticleSAGE open medical case reports2024

Rapid resolution of erythrodermic atopic dermatitis with upadacitinib: A case report.

Mysa Saad, Marina Guirguis, Camille Hamm, Reetesh Bose

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in SAGE open medical case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mysa SaadFaculty of Medicine, University of Ottawa, Roger Guindon Hall, Ottawa, ON, Canada.ORCID https://orcid.org/0000-0003-0611-559X
Marina GuirguisFaculty of Medicine, University of Ottawa, Roger Guindon Hall, Ottawa, ON, Canada.
Camille HammThe Ottawa Hospital Division of Dermatology, Ottawa, ON, Canada.ORCID https://orcid.org/0000-0001-5158-9319
Reetesh BoseFaculty of Medicine, University of Ottawa, Roger Guindon Hall, Ottawa, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atopic dermatitis is a chronic inflammatory skin disease that may progress to erythroderma in severe cases. Biologic agents such as dupilumab have recently become the mainstay of systemic treatment for moderate-to-severe cases, yet many patients remain refractory to therapy. Here, we present a case of erythrodermic atopic dermatitis, resistant to prednisone and dupilumab, with remarkably rapid achievement of remission following treatment with upadacitinib, an oral selective Janus kinase 1 inhibitor.

Indexed as

dupilumabErythrodermic atopic dermatitisJAK inhibitorprednisoneupadacitinib

Identifiers

PMID38881978
PMCPMC11179442

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.